HOME >> BIOLOGY >> NEWS
Biodesign and TGen form joint Center for Systems and Computational Biology

To help usher in a new era of molecular diagnostics and personalized medicine, ASU's Biodesign Institute and the Translational Genomics Research Institute (TGen) have teamed up to establish the Center for Systems and Computational Biology.

One of the first of its kind in the nation, the new center will accelerate the pace of biomedical research, directly impact patient care and provide new funding opportunities for both TGen and ASU. George Poste, director of the Biodesign Institute, and Jeffrey Trent, president and scientific director of TGen, will oversee the center. Systems biology is an emerging science that requires highly-integrated efforts between biologists, physicians, chemists, engineers and computer scientists. It combines "wet lab" research with "dry lab" computational technologies to help identify the molecular pathways relevant to disease. The resulting benefits to medicine may include better clinical trials, personalized therapies and improved diagnostics, drugs and vaccines.

"Much of our focus at Biodesign is in trying to understand biological function and the significance of disease at the most fundamental level: its molecular circuitry," said Poste. "This knowledge has enormous implications for every aspect of medicine, as well as other fields of science."

"At TGen, our focus is entirely on developing earlier diagnostics and smarter treatments," said Trent. "This new collaboration leverages the fast-growing field of computational biology to speed research and directly impact patients. Additionally, this partnership opens the door to new research and funding avenues for both TGen and ASU."

Accelerating Research

The Center for Systems and Computational Biology will use the extraordinary power of the ASU-TGen supercomputer to accelerate research by quickly analyzing the billions of data points generated by genetic research. For example, a researcher at a major U.S. university estimated it would take hi
'"/>

Contact: Joe Caspermeyer
joseph.caspermeyer@asu.edu
480-727-0369
Arizona State University
6-Feb-2006


Page: 1 2 3 4

Related biology news :

1. Biodesign Institute leads innovative project to prevent cancer
2. Biodesign Institute takes part in $14.4M NIH chemical defense grant
3. Biodesign Institute participates in first-of-its-kind coyote disaster preparedness drill
4. Biodesign Institute at ASU named lab of the year in international competition
5. Biodesign Institute awarded $3.2 million to develop vaccine to thwart biothreat
6. Biodesign Institute and TGen awarded grants to help lessen threat of radiological terrorist event
7. New joint replacement material developed at MGH put to first clinical use
8. It takes a village -- female ducks negotiate joint rearing of ducklings
9. Brown and OTS will jointly manage new ILTER network secretariat
10. How movement lubricates bone joints
11. Gene therapy research switches off joint inflammation; switches on genetic process of joint repair

Post Your Comments:
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
Cached News: